Advance in Cancer Pharmacoepidemiology

Topic Information

Dear Colleagues,

Cancer is a leading cause of mortality worldwide, and in recent years, novel treatments have been developed and approved that have improved the overall survival rate and quality of life of patients.

Cancer pharmacoepidemiology focuses on the real-world use, effects, and outcomes of cancer therapies, including chemotherapy, immunotherapy, targeted therapy, and supportive care medications, in large patient populations.

We are inviting you to contribute high-quality research relating to cancer pharmacoepidemiology that addresses research questions using innovative methods, for example, large-scale observational studies, target trial emulation, and systematic review with meta-analysis.

Topics of interest include, but are not limited to, the following:

• The real-world effectiveness and safety of cancer therapies;
• Cancer therapy patterns of use;
• The comparative effectiveness of cancer therapies;
• Health disparities in the use and outcomes of cancer therapies;
• The impact of novel cancer therapies on healthcare utilization and costs;
• Methodological papers to improve the study validity of cancer pharmacoepidemiology.

We invite submissions from researchers, clinicians, and other stakeholders involved in cancer care worldwide. All submitted papers will undergo a timely and rigorous peer-review process.

We look forward to receiving your submissions and advancing our understanding of cancer pharmacoepidemiology.

Dr. Shih-Chieh Shao
Dr. Edward Chia-Cheng Lai
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Cancers cancers	5.2	7.4	2009	18.2 Days	CHF 2900	Submit
Healthcare healthcare	2.8	2.7	2013	21.7 Days	CHF 2700	Submit
Pharmaceuticals pharmaceuticals	4.6	4.7	2004	15.7 Days	CHF 2900	Submit
Pharmaceutics pharmaceutics	5.4	6.9	2009	17 Days	CHF 2900	Submit
Pharmacoepidemiology pharmacoepidemiology	-	-	2022	15.0 days *	CHF 1000	Submit

* Median value for all MDPI journals in the first half of 2023.

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Cancers Healthcare Pharmaceuticals Pharmaceutics Pharmacoepidemiology

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

13 pages, 820 KiB  

Open AccessArticle

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System

by

Vera Martins

,

Mafalda Jesus

,

Luísa Pereira

,

Cristina Monteiro

,

Ana Paula Duarte

and

Manuel Morgado

Pharmaceuticals 2023, 16(10), 1340; https://doi.org/10.3390/ph16101340 - 22 Sep 2023

Viewed by 725

Abstract

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are a recent targeted therapy approved for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer. Abemaciclib, palbociclib and ribociclib demonstrated great efficacy and safety during clinical studies. However, [...] Read more.

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are a recent targeted therapy approved for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer. Abemaciclib, palbociclib and ribociclib demonstrated great efficacy and safety during clinical studies. However, differences in their adverse-event profiles have been observed. This work aims to describe the suspected adverse drug reactions (ADRs), such as leukopenia and thrombocytopenia, reported for each CDK4/6 inhibitor in the EudraVigilance (EV) database. Data on individual case safety reports (ICSRs) were obtained by accessing the European spontaneous reporting system via the EV website. Information on concomitant drug therapy, including fulvestrant, letrozole, anastrozole and exemestane, was also analyzed. A total of 1611 ICSRs were collected from the EV database. Most reports of palbociclib and ribociclib were classified as serious cases for both suspected leukopenia and thrombocytopenia ADRs. However, most patients had their leukopenia and thrombocytopenia recovered/resolved. On the contrary, reports of abemaciclib were mostly characterized as non-serious cases. Abemaciclib and palbociclib were often combined with fulvestrant, while ribociclib was generally associated with letrozole. Pharmacovigilance studies are crucial for the early identification of potential ADRs and to better differentiate the toxicity profile of the different CDK4/6 inhibitors, particularly in a real-world setting. Full article

(This article belongs to the Topic Advance in Cancer Pharmacoepidemiology)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1